Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Dendritic Cell Vaccination in High Risk Uveal Melanoma
NCT00929019Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2009
- Primary completion
- Apr 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous dendritic cells electroporated with mRNA encoding gp100 and tyrosinase in Uveal melanoma (UM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: In vivo immunological response at 2 years and Toxicity. Started Jun 2009; status: terminated.
02
Drugs
autologous dendritic cells electroporated with mRNA encoding gp100 and tyrosinase
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT00929019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929019.